Technical Analysis for MDGL - Madrigal Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 193.33 | -0.54% | -1.05 |
MDGL closed down 0.54 percent on Friday, April 26, 2024, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | -0.54% |
Alert | Time |
---|---|
Possible NR7 | about 12 hours ago |
Rose Above Lower Bollinger Band | about 17 hours ago |
Fell Below Previous Day's Low | about 17 hours ago |
Down 2 % | about 17 hours ago |
Down 1% | about 17 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medication Lipid Endocrine System Metabolic Disease Cholesterol Thyroid Hypercholesterolemia Dyslipidemia Glands Triglyceride Cardiovascular And Metabolic Diseases Hyperlipidemia Vascular And Metabolic Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medication Lipid Endocrine System Metabolic Disease Cholesterol Thyroid Hypercholesterolemia Dyslipidemia Glands Triglyceride Cardiovascular And Metabolic Diseases Hyperlipidemia Vascular And Metabolic Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 322.67 |
52 Week Low | 119.7604 |
Average Volume | 550,956 |
200-Day Moving Average | 201.56 |
50-Day Moving Average | 242.39 |
20-Day Moving Average | 230.29 |
10-Day Moving Average | 215.12 |
Average True Range | 13.20 |
RSI (14) | 28.57 |
ADX | 22.38 |
+DI | 12.99 |
-DI | 34.97 |
Chandelier Exit (Long, 3 ATRs) | 228.62 |
Chandelier Exit (Short, 3 ATRs) | 228.60 |
Upper Bollinger Bands | 266.83 |
Lower Bollinger Band | 193.74 |
Percent B (%b) | -0.01 |
BandWidth | 31.74 |
MACD Line | -12.63 |
MACD Signal Line | -7.98 |
MACD Histogram | -4.6493 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 203.20 | ||||
Resistance 3 (R3) | 202.85 | 199.22 | 201.56 | ||
Resistance 2 (R2) | 199.22 | 196.70 | 199.39 | 201.01 | |
Resistance 1 (R1) | 196.27 | 195.15 | 197.75 | 196.62 | 200.46 |
Pivot Point | 192.64 | 192.64 | 193.37 | 192.81 | 192.64 |
Support 1 (S1) | 189.69 | 190.12 | 191.17 | 190.04 | 186.20 |
Support 2 (S2) | 186.06 | 188.57 | 186.23 | 185.65 | |
Support 3 (S3) | 183.11 | 186.06 | 185.11 | ||
Support 4 (S4) | 183.46 |